#clinicaltrialresults — Public Fediverse posts

Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
#YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106390

Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
#YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106390

Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
#YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106390

Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.
#YonhapInfomax #NovoNordisk #CagriSema #EliLilly #ObesityDrug #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=106390

https://www.europesays.com/uk/638060/ Eli Lilly Drug Retatrutide Clinical Trial Results #ClinicalTrialResults #EliLillyDrug #GLP1s #Health #Medication #retatrutide #Semaglutide #TripleAgonist #TripleAgonistWeightLossMedication #UK #UnitedKingdom

Eli Lilly Drug Retatrutide Clinical Trial Results

3 min readEli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it…
#NewsBeep #News #Medication #AU #Australia #clinicaltrialresults #EliLillyDrug #GLP-1s #Health #Retatrutide #semaglutide #tripleagonist #tripleagonistweightlossmedication
https://www.newsbeep.com/au/353717/

https://www.europesays.com/ie/237256/ Eli Lilly Drug Retatrutide Clinical Trial Results #ClinicalTrialResults #Éire #EliLillyDrug #GLP1s #Health #IE #Ireland #Medication #retatrutide #semaglutide #TripleAgonist #TripleAgonistWeightLossMedication

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

MIPLYFFA Shows 5-Year Disease Stability in Niemann-Pick Type C Treatment Study

Zevra Therapeutics (NASDAQ:ZVRA) announced the presentation of four posters at…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Genetics #arimoclomolefficacy #clinicaltrialresults #diseasestabilizationdata #long-termtreatmentoutcomes #MIPLYFFA® #Niemann-PickdiseasetypeC #NPCtherapy #OLPRUVA #rarediseasetreatment #Science #SERGGconference #ZVRA
https://www.newsbeep.com/us/22973/